Olgu Sunumu
BibTex RIS Kaynak Göster

Salivary Gland Ductal Carcinoma of Accessory Parotid Gland

Yıl 2023, , 90 - 95, 31.12.2023

Adem Bora , Esra Nur Göksu , Tülay Koç

https://doi.org/10.7197/cmj.1210808

Öz

Salivary gland ductal carcinoma (SDC) is a rare, aggressive tumor with a highly malignant course and originates most frequently from the parotid gland among the major salivary glands. The incidence of accessory parotid gland (APG) varies between 21-56% and the incidence of tumor in APG is 1-8% of all parotid tumors. SDC is rarely seen in accessory glands. It was aimed to present our case, which was diagnosed with SDC in APG, in the light of the literature.

Anahtar Kelimeler

Salivary duct carcinoma accessory parotid gland diagnosis treatment

Kaynakça

  • 1. Simpson RH. Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification. Head Neck Pathol. 2013; 7 Suppl 1(Suppl 1):S48-58. doi: 10.1007/s12105-013-0456-x. Epub 2013 Jul 3. PMID: 23821208; PMCID: PMC3712088.
  • 2. Kleinsasser O, Klein HJ, Hübner G. Speichelgangearcinome. Ein denMilchgangcarcinomen der Brustdrüse analoge Gruppe von Speichldrüsentumoren[Salivary duct carcinoma. A group of salivary gland tumors analogous to mammaryduct carcinoma]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968; 192(1): 100-5.German. PMID: 4301301.
  • 3. You Y, Wang P, Wan X, Xu L, Gong Y, Zhang W. Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature. Onco Targets Ther. 2021; 14: 3481-3486. doi: 10.2147/OTT.S304900. PMID: 34093024; PMCID: PMC8169051.
  • 4. Valeri RM, Hadjileontis C, Skordalaki A, et al. Salivary duct carcinoma of the parotid gland: report of a rare case with a comparative study of aspiration cytology and histomorphology. Acta Cytol. 49: 61-64, 2005.
  • 5. Ceylan S, Yücel Z, Huq EG, Bora F. Tükürük bezi duktal karsinomuTurk Arch Otolaryngol, 2008; 46(4): 325-328 6. Yılmaz F, Gideroğlu K, Karaaslan K, Yiğit B, Gürel K, Yılmaz F, Boran Ç. Parotis Bezi Duktal Karsinomu: Olgu Sunumu Düzce Tıp Fakültesi Dergisi 2008; 3:64-67.
  • 7. Newberry TR, Kaufmann CR, Miller FR. Review of accessory parotid gland tumors: Pathologic incidence and surgical management. Am J Otolaryngol 2014;35:48‐52. 8. Al-Hashim MA, Al-Jazan NA. Salivary duct carcinoma of accessory parotid. J Family Community Med. 2017;24(3):200-202. doi:10.4103/jfcm.JFCM_141_16
  • 9. Seethala RR, Stenman G. Update from the 4th edition of the world health organization classification of head and neck tumours: tumors of the salivary gland. Head Neck Pathol. 2017;11(1): 55-67. doi:10.1007/s12105-017-0795-0.
  • 10. Higo R, Takahashi T, Nakata H, et al. Salivary duct carcinoma in the sinonasal tract. Eur Arch Otorhinolaryngol. 2007;264:561–563.
  • 11. D'heygere E, Meulemans J, Vander Poorten V. Salivary duct carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2018; 26(2)142-151. doi: 10.1097/MOO.0000000000000436. PMID: 29373327.
  • 12. Enomoto T, Aoki M, Miyagawa K, Matsumoto J, Kobayashi H, Takeuchi T, Abe H, Nonaka M, Sakata T, Inoue T, Nabeshima K. A Case of Salivary Duct Carcinoma Intracranial Invasion due to Perineural Invasion Through the Facial Nerve. World Neurosurg. 2020; 140: 332-337. doi: 10.1016/j.wneu.2020.05.180. Epub 2020 May 27.
  • 13. Lazard DS, Baglin AC, Baujat B, Cox A, Condette-Auliac S, Chabolle F. Mandibular osteosclerotic lesion of a parotid salivary duct carcinoma: demonstration of the neural tropism of these tumors. Eur Ann Otorhinolaryngol Head Neck Dis. 2010; 127(5): 18992. doi: 10.1016/j.anorl.2010.07.007. Epub 2010 Oct 8. PMID: 20934935.
  • 14. Ahn S, Kim Y, Oh YL. Fine needle aspiration cytology of benign salivary gland tumors with myoepithelial cell participation: an institutional experience of 575 cases. Acta Cytol. 2013;57(6):567–74.
  • 15. Rossi ED, Faquin WC, Baloch Z, Barkan GA, Foschini MP, Pusztaszeri M, et al. The Milan System for Reporting Salivary Gland Cytopathology: Analysis and suggestions of initial survey. Cancer Cytopathol. 2017. https://doi.org/10.1002/cncy.21898.
  • 16. Masubuchi T,Tada Y, Maruya S, Osamura Y, Kamata S, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, Nagao T. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol. 2015; 20:35–44DOI 10.1007/s10147-014-0674-6
  • 17. Sreevathsa MR, Harsha A H. Accessory parotid gland tumors. Ann Maxillofac Surg. 2012; 2(1): 90–93. doi: 10.4103/2231-0746.95334
  • 18. Han X, Zhang X, Gao Y, Pang P, Liu F, Sun C. Management and prognosis of cancers in the accessory parotid gland. J Int Med Res. 2018; 46(12): 4930–4933. doi: 10.1177/0300060518767792.

Yıl 2023, , 90 - 95, 31.12.2023

Adem Bora , Esra Nur Göksu , Tülay Koç

https://doi.org/10.7197/cmj.1210808

Öz

Anahtar Kelimeler

Salivary duct carcinoma accessory parotid gland diagnosis treatment

Kaynakça

  • 1. Simpson RH. Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification. Head Neck Pathol. 2013; 7 Suppl 1(Suppl 1):S48-58. doi: 10.1007/s12105-013-0456-x. Epub 2013 Jul 3. PMID: 23821208; PMCID: PMC3712088.
  • 2. Kleinsasser O, Klein HJ, Hübner G. Speichelgangearcinome. Ein denMilchgangcarcinomen der Brustdrüse analoge Gruppe von Speichldrüsentumoren[Salivary duct carcinoma. A group of salivary gland tumors analogous to mammaryduct carcinoma]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968; 192(1): 100-5.German. PMID: 4301301.
  • 3. You Y, Wang P, Wan X, Xu L, Gong Y, Zhang W. Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature. Onco Targets Ther. 2021; 14: 3481-3486. doi: 10.2147/OTT.S304900. PMID: 34093024; PMCID: PMC8169051.
  • 4. Valeri RM, Hadjileontis C, Skordalaki A, et al. Salivary duct carcinoma of the parotid gland: report of a rare case with a comparative study of aspiration cytology and histomorphology. Acta Cytol. 49: 61-64, 2005.
  • 5. Ceylan S, Yücel Z, Huq EG, Bora F. Tükürük bezi duktal karsinomuTurk Arch Otolaryngol, 2008; 46(4): 325-328 6. Yılmaz F, Gideroğlu K, Karaaslan K, Yiğit B, Gürel K, Yılmaz F, Boran Ç. Parotis Bezi Duktal Karsinomu: Olgu Sunumu Düzce Tıp Fakültesi Dergisi 2008; 3:64-67.
  • 7. Newberry TR, Kaufmann CR, Miller FR. Review of accessory parotid gland tumors: Pathologic incidence and surgical management. Am J Otolaryngol 2014;35:48‐52. 8. Al-Hashim MA, Al-Jazan NA. Salivary duct carcinoma of accessory parotid. J Family Community Med. 2017;24(3):200-202. doi:10.4103/jfcm.JFCM_141_16
  • 9. Seethala RR, Stenman G. Update from the 4th edition of the world health organization classification of head and neck tumours: tumors of the salivary gland. Head Neck Pathol. 2017;11(1): 55-67. doi:10.1007/s12105-017-0795-0.
  • 10. Higo R, Takahashi T, Nakata H, et al. Salivary duct carcinoma in the sinonasal tract. Eur Arch Otorhinolaryngol. 2007;264:561–563.
  • 11. D'heygere E, Meulemans J, Vander Poorten V. Salivary duct carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2018; 26(2)142-151. doi: 10.1097/MOO.0000000000000436. PMID: 29373327.
  • 12. Enomoto T, Aoki M, Miyagawa K, Matsumoto J, Kobayashi H, Takeuchi T, Abe H, Nonaka M, Sakata T, Inoue T, Nabeshima K. A Case of Salivary Duct Carcinoma Intracranial Invasion due to Perineural Invasion Through the Facial Nerve. World Neurosurg. 2020; 140: 332-337. doi: 10.1016/j.wneu.2020.05.180. Epub 2020 May 27.
  • 13. Lazard DS, Baglin AC, Baujat B, Cox A, Condette-Auliac S, Chabolle F. Mandibular osteosclerotic lesion of a parotid salivary duct carcinoma: demonstration of the neural tropism of these tumors. Eur Ann Otorhinolaryngol Head Neck Dis. 2010; 127(5): 18992. doi: 10.1016/j.anorl.2010.07.007. Epub 2010 Oct 8. PMID: 20934935.
  • 14. Ahn S, Kim Y, Oh YL. Fine needle aspiration cytology of benign salivary gland tumors with myoepithelial cell participation: an institutional experience of 575 cases. Acta Cytol. 2013;57(6):567–74.
  • 15. Rossi ED, Faquin WC, Baloch Z, Barkan GA, Foschini MP, Pusztaszeri M, et al. The Milan System for Reporting Salivary Gland Cytopathology: Analysis and suggestions of initial survey. Cancer Cytopathol. 2017. https://doi.org/10.1002/cncy.21898.
  • 16. Masubuchi T,Tada Y, Maruya S, Osamura Y, Kamata S, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, Nagao T. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol. 2015; 20:35–44DOI 10.1007/s10147-014-0674-6
  • 17. Sreevathsa MR, Harsha A H. Accessory parotid gland tumors. Ann Maxillofac Surg. 2012; 2(1): 90–93. doi: 10.4103/2231-0746.95334
  • 18. Han X, Zhang X, Gao Y, Pang P, Liu F, Sun C. Management and prognosis of cancers in the accessory parotid gland. J Int Med Res. 2018; 46(12): 4930–4933. doi: 10.1177/0300060518767792.
Toplam 16 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Case Reports
Yazarlar

Adem Bora 0000-0002-5036-0595

Esra Nur Göksu 0000-0002-1919-8040

Tülay Koç 0000-0001-8612-0238

Yayımlanma Tarihi 31 Aralık 2023
Kabul Tarihi 28 Aralık 2023
Yayımlandığı Sayı Yıl 2023

Kaynak Göster

AMA Bora A, Göksu EN, Koç T. Salivary Gland Ductal Carcinoma of Accessory Parotid Gland. CMJ. Aralık 2023;45(4):90-95. doi:10.7197/cmj.1210808